Pesquisar
Uniqure NV
QUREAdicionar à lista de desejos
45.640USD
-0.420-0.91%
Horário de mercado （ET）Cotações atrasadas em 15 min
2.88BValor de mercado
PerdaP/L TTM
Mais detalhes de Uniqure NV Empresa
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Informações de Uniqure NV
Código da empresaQURE
Nome da EmpresaUniqure NV
Data de listagemFeb 05, 2014
CEOKapusta (Matthew)
Número de funcionários209
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 05
EndereçoPaasheuvelweg 25a
CidadeAMSTERDAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal1105 BP
Telefone31202406000
Sitehttps://www.uniqure.com/
Código da empresaQURE
Data de listagemFeb 05, 2014
CEOKapusta (Matthew)
Executivos da empresa Uniqure NV
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
63.73K
-31.38%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.69K
-0.17%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
27.52K
+20.19%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
25.93K
+21.43%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
63.73K
-31.38%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.69K
-0.17%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Perguntas frequentes
Quem são os cinco principais acionistas de Uniqure NV?
Os cinco principais acionistas de Uniqure NV são: Mr. Christian Klemt, CPA
Quantas instituições possuem ações da Uniqure NV (QURE)?
Em 2026Q1, 481 instituições possuíam ações da Uniqure NV, com valor de mercado aproximado de 65.80M, representando 104.34% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 1601871.00.